Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 3266 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed671    
    Printed25    
    Emailed0    
    PDF Downloaded124    
    Comments [Add]    

Recommend this journal

 
REVIEW ARTICLE
Year : 2003  |  Volume : 45  |  Issue : 1  |  Page : 10-15

The use of Atypical Antipsychotics in Bipolar Spectrum Disorders


Department of Psychiatry, Ludwig-Maxmilians University, Nussbaumstrasse 7, 80336 Munich, Germany

Correspondence Address:
H Grunze
Department of Psychiatry, Ludwig-Maxmilians University, Nussbaumstrasse 7, 80336 Munich, Germany

Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21206806

Rights and PermissionsRights and Permissions

Viewed in the context of ever-expanding conceptual boundaries for the diagnosis of bipolar disorder including the spectrum concept of DSM-IV, or even beyond (Akiskal and Pinto, 1999), it becomes obvious that lithium is the treatment of choice in a minority' of patients only (Bowden et al, 2000). This article reviews what additional benefit atypical antipsychotics may provide in patients with bipolar disorder. Due both to tradition and to the regulatory requirements in the USA (FDA) and European Union (EMEA), the main target of clinical trials with atypical antipsychotics has been typical manic disorder. More recently, a significant subgroup of atypical patients, e.g., with mixed states, marked psychosis, or rapid cycling, have participated in these studies to allow an estimation of the value of atypical antipsychotics in these conditions. For the purposes of filing applications for registration with the regulatory agencies, the existing evidence is probably weak, however; from a clinical perspective, it is important that most atypical antipsychotics have also been tested in combination treatments. Finally, first data are now available on long-term prophylactic efficacy of atypical antipsychotics. These combined efficacy data definitely support the use of atypical antipsychotics in bipolar disorder, and it is now the time to collect more experience with these substances in severely ill patients in clinical settings.



[PDF]*

        

Print this article         Email this article